featured
Maintenance Olaparib Does Not Adversely Impact Patient-Centered Outcomes in Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient-Centred Outcomes and Effect of Disease Progression on Health Status in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Receiving Maintenance Olaparib or Placebo (SOLO1): A Randomised, Phase 3 Trial
Lancet Oncol 2021 Apr 13;[EPub Ahead of Print], M Friedlander, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, A Lisyanskaya, GS Sonke, C Gourley, S Banerjee, A Oza, A González-Martín, C Aghajanian, WH Bradley, J Liu, C Mathews, F Selle, A Lortholary, ES Lowe, R Hettle, E Flood, E Parkhomenko, P DiSilvestroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.